Publications by authors named "Stephan R Bohl"

Claim this Profile
M
Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with rearrangement or mutation to venetoclax.
Johanna Rausch, Margarita M Dzama, Nadezda Dolgikh, Hanna L Stiller, Stephan R Bohl

Haematologica· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dynamic BH3 profiling identifies pro-apoptotic drug combinations for the treatment of malignant pleural mesothelioma.
Danielle S Potter, Ruochen Du, Stephan R Bohl, Kin-Hoe Chow, Keith L Ligon

Nat Commun· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma.
Yuen Lam Dora Ng, Evelyn Ramberger, Stephan R Bohl, Anna Dolnik, Christian Steinebach

Nat Commun· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myeloma.
Stephan R Bohl, Laura K Schmalbrock, Imke Bauhuf, Tatjana Meyer, Anna Dolnik

Blood Adv· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia.
Shruti Bhatt, Marissa S Pioso, Elyse Anne Olesinski, Binyam Yilma, Jeremy A Ryan, Stephan R Bohl

Cancer Cell· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Granulocyte transfusions - bridging to allogeneic hematopoietic stem cell transplantation.
Thanh Mai Nguyen, Katrina Scholl, Irina Idler, Verena Wais, Sixten Körper, Stephan R Bohl

Leuk Lymphoma· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New Targeted Agents in Acute Myeloid Leukemia: New Hope on the Rise.
Stephan R Bohl, Lars Bullinger, Frank G Rücker

Int J Mol Sci· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epigenetic therapy: azacytidine and decitabine in acute myeloid leukemia.
Stephan R Bohl, Lars Bullinger, Frank G Rücker

Expert Rev Hematol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thrombotic Microangiopathy after Allogeneic Stem Cell Transplantation: A Comparison of Eculizumab Therapy and Conventional Therapy.
Stephan R Bohl, Florian Kuchenbauer, Stefanie von Harsdorf, Nadine Kloevekorn, Stefan S Schönsteiner

Biol Blood Marrow Transplant· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gene expression analysis of decitabine treated AML: high impact of tumor suppressor gene expression changes.
Stephan R Bohl, Anna Dolnik, Thomas Jensen, Katharina M Lang, Björn Hackanson

Leuk Lymphoma· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer stem cells: characteristics and their potential role for new therapeutic strategies.
Stephan R Bohl, Andreas Pircher, Wolfgang Hilbe

Onkologie· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis